Basic fibroblast growth factor: Effects on matrix remodeling, receptor expression, and transduction pathway in human periosteal fibroblasts with FGFR2 gene mutation

Journal of Interferon and Cytokine Research

Volumn 22, Issue 6, 2002, Pages 621-630

  Bodo, Maria ^a   Lilli, Cinzia ^a   Aisa, Maria Cristina ^a   Scapoli, Luca ^b   Bellucci, Catia ^a   Rinaldi, Eliana ^b   Tosi, Lara ^b   Baroni, Tiziano ^a   Conte, Carmela ^a   Bellocchio, Silvia ^a   Carinci, Francesco ^b   Stabellini, Giordano ^c   Carinci, Paolo ^d  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBRONECTIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; PHOSPHOPROTEIN; PHOSPHOTYROSINE; PROTEIN ANTIBODY; PROTEINASE;

ADOLESCENT; ADULT; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CASE REPORT; CELL SURFACE; CONTROLLED STUDY; CROUZON SYNDROME; ENZYME ACTIVITY; FIBROBLAST; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; CATHEPSIN B; CRANIOFACIAL DYSOSTOSIS; ENDOPEPTIDASES; EXTRACELLULAR MATRIX; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; FIBRONECTINS; GRB2 ADAPTOR PROTEIN; HUMANS; KALLIKREINS; PERIOSTEUM; PHOSPHORYLATION; PLASMINOGEN ACTIVATORS; POINT MUTATION; PROTEINS; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION; TYROSINE;

EID: 18544371817     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/10799900260100105     Document Type: Article

References (56)

1. Cranial sutures as intramembranous bone growth sites
2. Regulation of proliferation and osteochondrogenic differentiation of periosteum-derived cells by transforming growth factor-β and basic fibroblast growth factor
3. Merging the old skeletal biology with the new. II. Molecular aspects of bone formation and bone growth
4. Dura mater maintains rat cranial sutures in vitro by regulating suture cell proliferation and collagen production
5. Cranial suture obliteration is induced by removal of transforming growth factor (TGF)-beta 3 activity and prevented by removal of TGF-beta 2 activity from fetal rat calvaria in vitro
6. Transforming growth factor-beta 2 and TGF-beta 3 regulate fetal rat cranial suture morphogenesis by regulating rates of cell proliferation and apoptosis
7. Integration of FGF and TWIST in calvarial bone and suture development
8. FGF signaling in skeletal development
9. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high-affinity receptor
10. Heparian sulfate proteoglycans as transducers of FGF-2 signalling
11. Heparan sulfate potentiates the autocrine action of basic fibroblast growth factor in astrocytes: An in vivo and in vitro study
12. FGF-, BMP- and Shh-mediated signalling pathways in the regulation of cranial suture morphogenesis and calvarial bone development
13. Fibroblast growth factor receptor tyrosine kinases: Molecular analysis and signal transduction
14. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation
15. The ins and outs of fibroblast growth factors
16. Spatio-temporal expression of FGFR1, 2 and 3 genes during human embryo-fetal ossification
17. Fibroblast-growth-factor receptor mutations in human skeletal disorders
18. Clinical spectrum of fibroblast growth factor receptor mutations
19. A novel mutation, Ala315Ser, in FGFR2: A gene-environment interaction leading to craniosynostosis
20. Craniosynostosis: Genes and mechanisms
21. Fibroblast growth factor receptors: Lessons from the genes
22. Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR2) and FGFR2/Neuchimeras
23. Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain
24. The Ser252Trp fibroblast growth factor receptor-2 (FGFR-2) mutation induces PKC-independent downregulation of FGFR-2 associated with premature calvaria osteoblast differentiation
25. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts
26. Crouzon's disease correlates with low fibroblastic growth factor receptor activity in stenosed cranial sutures
27. Apert's syndrome correlates with low fibroblast growth factor receptor activity in stenosed cranial sutures
28. Effect of interleukins on Crouzon fibroblast phenotype in vitro. Release of cytokines and IL-6 mRNA expression
29. Apert's syndrome: Differential in vitro production of matrix macromolecules and its regulation by interleukins
30. Interleukin pattern of Apert fibroblast in vitro
31. A regulatory role of fibroblast growth factor in the expression of decorin, biglycan, betaglycan and syndecan in osteoblasts from patients with Crouzon's syndrome
32. 1 (I) gene expression in Crouzon fibroblast treated with basic fibroblast growth factor
33. Role of the extracellular matrix and growth factors in skull morphogenesis and in the pathogenesis of craniosynostosis
34. Apoptosis in murine calvarial bone and suture development
35. FGFR-2 mutations in Pfeiffer syndrome
36. Binding of soluble form of fibroblast surface protein, fibronectin, to collagen
37. High and low affinity binding sites for basic fibroblast growth factor on cultured cells: Absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells
38. Potentiation and inhibition of bFGF binding by heparin: A model for regulation of cellular response
39. The attractions of proteins for small molecules and ions
40. Craniosynostosis: From a clinical description to an understanding of bone formation of the skull
41. Mutations in fibroblast growth factor receptors: Phenotypic consequences during eukaryotic development
42. Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice
43. Degradation of extracellular matrix proteins by human cathepsin B from normal and tumour tissues
44. Cathepsin B activity in normal human osteoblast-like cells and human osteoblastic osteosarcoma cells (MG63): Regulation by interleukin-1β and parathyroid hormone
45. Matrix metalloproteinases
46. Matrix metalloproteinase degradation of extracellular matrix: Biological consequences
47. Ultrastructural immunolocalization of fibronectin epiphyseal and metaphyseal bone of young rats
48. Glucocorticoids inhibit fibronectin synthesis and messenger ribonucleic acid levels in cultured fetal rat parietal bones
49. Proteolytic remodeling of extracellular matrix
50. Extracellular matrix remodelling and cellular differentiation
51. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells
52. Decreased proliferation and altered differentiation in osteoblasts from genetically and clinically distinct craniosynostotic disorders
53. Mutation associated with Crouzon syndrome causes ligand-independent dimerization and activation of FGF receptor-2
54. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha
55. Five isoforms of the phosphatidylinositol 3-kinase regulatory subunit exhibit different associations with receptor tyrosine kinases and their tyrosine phosphorylations
56. Diversification of cardiac insulin signaling involves the p85 alpha/beta subunits of phosphatidylinositol 3-kinase